Equillium (EQ) Total Non-Current Liabilities (2017 - 2026)
Equillium (EQ) posted quarterly Total Non-Current Liabilities of $3.6 million for Q1 2026, down 41.54% year-over-year from $6.2 million in Q1 2025, and up 9.3% quarter-over-quarter from $3.3 million in Q4 2025.
Equillium (EQ) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Total Non-Current Liabilities for 10 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 41.54% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (down 41.54% YoY), while the FY2025 annual figure was $3.3 million, down 49.72% from the prior year.
- Total Non-Current Liabilities advanced to $3.6 million in Q1 2026 per EQ's latest filing, from $3.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $46.5 million in Q4 2022 and bottomed at $3.3 million in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $19.3 million across 5 years, with a median of $20.5 million in 2022.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 145.92% — and 2024, when it plunged 76.6%.
- Equillium's Total Non-Current Liabilities stood at $46.5 million in 2022, then plunged by 39.85% to $28.0 million in 2023, then slumped by 76.6% to $6.5 million in 2024, then sank by 49.72% to $3.3 million in 2025, then increased by 9.3% to $3.6 million in 2026.
- Business Quant data shows EQ's Total Non-Current Liabilities at $3.6 million in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 2.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.65 Mn |
| Mar 31, 2026 | 3.60 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 7.34 Mn |
| Mar 31, 2025 | 6.15 Mn |
| Dec 31, 2024 | 6.54 Mn |
| Sep 30, 2024 | 11.28 Mn |
| Jun 30, 2024 | 20.43 Mn |
| Mar 31, 2024 | 22.50 Mn |
| Dec 31, 2023 | 27.96 Mn |
| Sep 30, 2023 | 31.12 Mn |
| Jun 30, 2023 | 31.78 Mn |
| Mar 31, 2023 | 42.52 Mn |
| Dec 31, 2022 | 46.48 Mn |
| Sep 30, 2022 | 20.47 Mn |
| Jun 30, 2022 | 22.21 Mn |
| Mar 31, 2022 | 21.61 Mn |
| Dec 31, 2021 | 18.90 Mn |
| Sep 30, 2021 | 16.65 Mn |